RU2016135555A3 - - Google Patents

Download PDF

Info

Publication number
RU2016135555A3
RU2016135555A3 RU2016135555A RU2016135555A RU2016135555A3 RU 2016135555 A3 RU2016135555 A3 RU 2016135555A3 RU 2016135555 A RU2016135555 A RU 2016135555A RU 2016135555 A RU2016135555 A RU 2016135555A RU 2016135555 A3 RU2016135555 A3 RU 2016135555A3
Authority
RU
Russia
Application number
RU2016135555A
Other languages
Russian (ru)
Other versions
RU2016135555A (ru
RU2713179C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016135555A publication Critical patent/RU2016135555A/ru
Publication of RU2016135555A3 publication Critical patent/RU2016135555A3/ru
Application granted granted Critical
Publication of RU2713179C2 publication Critical patent/RU2713179C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2016135555A 2014-02-21 2015-02-20 Антимитотические амиды для лечения рака и пролиферативных заболеваний RU2713179C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
US61/942,956 2014-02-21
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Publications (3)

Publication Number Publication Date
RU2016135555A RU2016135555A (ru) 2018-03-28
RU2016135555A3 true RU2016135555A3 (https=) 2018-10-05
RU2713179C2 RU2713179C2 (ru) 2020-02-04

Family

ID=52684675

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016135555A RU2713179C2 (ru) 2014-02-21 2015-02-20 Антимитотические амиды для лечения рака и пролиферативных заболеваний

Country Status (15)

Country Link
US (5) US10016398B2 (https=)
EP (1) EP3107909B1 (https=)
JP (1) JP6506313B2 (https=)
KR (1) KR102420508B1 (https=)
CN (2) CN114634483B (https=)
AU (1) AU2015218775C1 (https=)
BR (1) BR112016019161B1 (https=)
CA (1) CA2940237C (https=)
ES (1) ES2893374T3 (https=)
IL (1) IL247293B (https=)
MX (1) MX390530B (https=)
RU (1) RU2713179C2 (https=)
SG (2) SG11201606869TA (https=)
WO (1) WO2015127284A2 (https=)
ZA (1) ZA201606471B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders
CN106727583A (zh) * 2016-12-12 2017-05-31 范旭升 一种治疗舒张性心衰的药物组合物
US11377436B2 (en) * 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR20250173438A (ko) * 2024-05-30 2025-12-10 삼진제약주식회사 Nr2f6 억제제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
BR0111280A (pt) * 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
CN1976703A (zh) * 2004-06-30 2007-06-06 诺瓦提斯公司 通过使用外排泵抑制剂增加肽脱甲酰基酶抑制剂敏感性的方法
US20090156646A1 (en) * 2005-08-11 2009-06-18 Takeda Pharmaceutical Company Limited Pyridylphenol compound and use thereof
US20070254926A1 (en) * 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
EP2086966B1 (en) 2006-11-17 2011-09-14 GlaxoSmithKline LLC 2-carboxy thiophene derivatives as anti viral agents
BRPI0810641A2 (pt) * 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
WO2010039236A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
HUE024568T2 (hu) * 2009-09-11 2016-02-29 Amgen Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin antimitotikus szerre rezisztens rák kezelésében történõ alkalmazásra
DK2563776T3 (en) * 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
WO2011142151A1 (ja) * 2010-05-14 2011-11-17 シャープ株式会社 携帯型情報端末およびその制御方法
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US8859546B2 (en) * 2011-01-21 2014-10-14 Abbvie Inc. Picolinamide inhibitors of kinases
BR112013020270A2 (pt) * 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2704701B1 (en) * 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
US20140242099A1 (en) 2011-10-28 2014-08-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders

Also Published As

Publication number Publication date
IL247293B (en) 2021-01-31
RU2016135555A (ru) 2018-03-28
AU2015218775A1 (en) 2016-08-25
MX2016010877A (es) 2017-05-04
SG10202000590SA (en) 2020-03-30
US12383533B2 (en) 2025-08-12
CN106068263A (zh) 2016-11-02
EP3107909B1 (en) 2021-07-14
US20260034101A1 (en) 2026-02-05
MX390530B (es) 2025-03-20
WO2015127284A2 (en) 2015-08-27
KR102420508B1 (ko) 2022-07-13
JP2017506267A (ja) 2017-03-02
CA2940237C (en) 2023-03-07
KR20160116009A (ko) 2016-10-06
ES2893374T3 (es) 2022-02-08
JP6506313B2 (ja) 2019-04-24
US20170172984A1 (en) 2017-06-22
US20220008395A1 (en) 2022-01-13
EP3107909A2 (en) 2016-12-28
AU2015218775B2 (en) 2019-06-20
CN114634483A (zh) 2022-06-17
AU2015218775C1 (en) 2020-01-16
BR112016019161A2 (https=) 2017-08-15
US20200397758A1 (en) 2020-12-24
RU2713179C2 (ru) 2020-02-04
IL247293A0 (en) 2016-09-29
US20180325871A1 (en) 2018-11-15
BR112016019161B1 (pt) 2022-12-20
CN114634483B (zh) 2024-08-13
CA2940237A1 (en) 2015-08-27
US11129813B2 (en) 2021-09-28
US10772872B2 (en) 2020-09-15
US10016398B2 (en) 2018-07-10
WO2015127284A3 (en) 2015-10-15
ZA201606471B (en) 2025-06-25
SG11201606869TA (en) 2016-09-29

Similar Documents

Publication Publication Date Title
BR122019013525A2 (https=)
BR112016017664A2 (https=)
BR112016017872A2 (https=)
BR112016015813A2 (https=)
BR112016016834A2 (https=)
BR112016018293A2 (https=)
BR112016017913A2 (https=)
BR112016017950A2 (https=)
BR112016017265A2 (https=)
BR112016012568A2 (https=)
BR112016017526A2 (https=)
BR112016015798A2 (https=)
BR112016017660A2 (https=)
BR112016015779A2 (https=)
BR112016017927A2 (https=)
BR112016015768A2 (https=)
BR112016017739A2 (https=)
BR112016017221A2 (https=)
BR112016016798A2 (https=)
BR112014024551A2 (https=)
AP2017009684A0 (https=)
BR102015031789A2 (https=)
BR112016017702A2 (https=)
BR112016016442A2 (https=)
BR112016017378A2 (https=)